Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes From Study P-2001

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 01期
关键词：
NEDD8-ACTIVATING ENZYME; INHIBITOR;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 13
页数：3
相关论文
共 50 条
  • [21] Azacitidine A Review of its Use in Higher-Risk Myelodysplastic Syndromes/Acute Myeloid Leukaemia
    Keating, Gillian M.
    DRUGS, 2009, 69 (17) : 2501 - 2518
  • [22] Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Sekeres, Mikkael A.
    Watts, Justin
    Radinoff, Atanas
    Sangerman, Montserrat Arnan
    Cerrano, Marco
    Lopez, Patricia Font
    Zeidner, Joshua F.
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Ades, Lionel
    LEUKEMIA, 2021, 35 (07) : 2119 - 2124
  • [23] Effectiveness of azacitidine for the treatment of higher-risk myelodysplastic syndromes in daily practice: the authors' reply
    Bernal, T.
    Martinez-Camblor, P.
    Sanchez-Garcia, J.
    Sanz, G.
    LEUKEMIA, 2016, 30 (03) : 740 - 741
  • [24] Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study
    Sallman, David A.
    Al Malki, Monzr M.
    Asch, Adam S.
    Wang, Eunice S.
    Jurcic, Joseph G.
    Bradley, Terrence J.
    Flinn, Ian W.
    Pollyea, Daniel A.
    Kambhampati, Suman
    Tanaka, Tiffany N.
    Zeidner, Joshua F.
    Garcia-Manero, Guillermo
    Jeyakumar, Deepa
    Komrokji, Rami
    Lancet, Jeffrey
    Kantarjian, Hagop M.
    Gu, Lin
    Zhang, Yajia
    Tan, Anderson
    Chao, Mark
    O'Hear, Carol
    Ramsingh, Giridharan
    Lal, Indu
    Vyas, Paresh
    Daver, Naval G.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (15) : 2815 - +
  • [25] Final Results from a Phase I Combination Study of Lenalidomide and Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    List, Alan F.
    Cuthbertson, David
    Paquette, Ronald
    Latham, Deborah
    Afable, Manual
    Paulic, Katarina
    Loughran, Thomas P., Jr.
    Maciejewski, Jaroslaw P.
    BLOOD, 2008, 112 (11) : 88 - 89
  • [26] Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML
    Mikkael A. Sekeres
    Justin Watts
    Atanas Radinoff
    Montserrat Arnan Sangerman
    Marco Cerrano
    Patricia Font Lopez
    Joshua F. Zeidner
    Maria Diez Campelo
    Carlos Graux
    Jane Liesveld
    Dominik Selleslag
    Nikolay Tzvetkov
    Robert J. Fram
    Dan Zhao
    Jill Bell
    Sharon Friedlander
    Douglas V. Faller
    Lionel Adès
    Leukemia, 2021, 35 : 3637 - 3637
  • [27] Phase 2 Study of Pevonedistat plus Azacitidine versus Azacitidine in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Low-Blast Acute Myelogenous Leukemia (LB-AML) (NCT02610777): Subset Analysis in Higher-Risk MDS
    Watts, Justin
    Ades, Lionel
    Radinoff, Atanas
    Arnan Sangerman, Montserrat
    Cerrano, Marco
    Font Lopez, Patricia
    Zeidner, Joshua
    Campelo, Maria Diez
    Graux, Carlos
    Liesveld, Jane
    Selleslag, Dominik
    Tzvetkov, Nikolay
    Fram, Robert J.
    Zhao, Dan
    Bell, Jill
    Friedlander, Sharon
    Faller, Douglas V.
    Sekeres, Mikkael A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S323 - S324
  • [28] A phase 1b study of glasdegib plus azacitidine in patients with untreated acute myeloid leukemia and higher-risk myelodysplastic syndromes
    Sekeres, Mikkael A.
    Schuster, Michael
    Joris, Magalie
    Krauter, Juergen
    Maertens, Johan
    Breems, Dimitri
    Gyan, Emmanuel
    Kovacsovics, Tibor
    Verma, Amit
    Vyas, Paresh
    Wang, Eunice S.
    Ching, Keith
    O'Brien, Thomas
    Stampino, Corrado Gallo
    Ma, Weidong Wendy
    Kudla, Arthur
    Chan, Geoffrey
    Zeidan, Amer M.
    ANNALS OF HEMATOLOGY, 2022, 101 (08) : 1689 - 1701
  • [29] Azacitidine Alone Or The Combination With Valproic Acid As a Bridge Therapy For Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes Before Transplantation
    Cabrera, Cristina Calderon
    Falantes, Jose F.
    Gomez, Marina
    Parody, Rocio
    Malaver, Francisco J. Marquez
    Martino, Marla L.
    Gonzalez, Jose
    Montero, Isabel
    Espigado, Ildefonso
    Perez-Simon, Jose Antonio
    BLOOD, 2013, 122 (21)
  • [30] The Safety and Tolerability of Azacitidine (AZA) Are Comparable in Patients with Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndromes (MDS)
    Seymour, John F.
    Silverman, Lewis R.
    Doehner, Hartmut
    Fenaux, Pierre
    Mufti, Ghulam J.
    Santini, Valeria
    Minden, Mark D.
    Stone, Richard M.
    Lucy, Lela M.
    Songer, Stephen
    Dougherty, Donna
    Hinkle, Randy
    Gambini, Dominique
    Beach, C. L.
    Dombret, Herve
    BLOOD, 2015, 126 (23)
12345